The Conversation (0)
August 04, 2024
Cardiex Limited (ASX:CDX) (the “Company”) will host an investor webinar on Tuesday, 6 August 2024 at 9:00am (AEST)/ Monday, 5 August 2024 at 4:00pm (PDT).
The webinar will be hosted by Cardiex’s CEO Craig Cooper who will be joined by Niall Cairns (Executive Chairman), Catherine Liao (Chief Strategy Officer), Mark Gorelick (Chief Product Officer), Brian Schaechter (Senior Director of Sales - Pharmaceutical), and Rosemarie Diehl (Senior Director of Demand Generation), who will be providing an update on the Company’s business, product, sales, and operating activities for the last quarter.
Webinar details:
Date: Tuesday, 6 August 2024 (AEST)/ Monday, 5 August 2024 (PDT)
Time: 9:00am (AEST)/4:00pm (PDT)
Registration: https://us06web.zoom.us/webinar/register/WN_IyGdGU-vSXKr5rydWEvAEQ
Dial in Details: After registering, you will receive a confirmation email containing information about joining the webinar.
Click here for the full ASX Release
This article includes content from CardieX Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
CDX:AU
INN Article Notification
29 August 2025
FY25 Preliminary Results Summary and Company Update
Cardiex Limited (CDX:AU) has announced FY25 Preliminary Results Summary and Company UpdateDownload the PDF here. Keep Reading...
29 August 2025
Appendix 4E
Cardiex Limited (CDX:AU) has announced Appendix 4EDownload the PDF here. Keep Reading...
31 July 2025
June Quarterly Appendix 4C
Cardiex Limited (CDX:AU) has announced June Quarterly Appendix 4CDownload the PDF here. Keep Reading...
31 July 2025
June Quarterly Activities Report
Cardiex Limited (CDX:AU) has announced June Quarterly Activities ReportDownload the PDF here. Keep Reading...
24 June 2025
Results of Entitlement Offer
Cardiex Limited (CDX:AU) has announced Results of Entitlement OfferDownload the PDF here. Keep Reading...
28 January
Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit
Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults -- a significant clinical and financial challenge... Keep Reading...
14 January
Top 3 Medical Device ETFs for Investors in 2026
Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or... Keep Reading...
06 January
Top 3 Small-cap Medical Device Stocks (Updated January 2026)
The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).Wearable medical devices and the use of artificial intelligence in medical... Keep Reading...
05 January
Pathways to Commercialising Biotech Innovations
In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
09 September 2025
How to Invest in Medical Device Stocks and ETFs
The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and... Keep Reading...
13 March 2025
BlinkLab Completes First Patient Test for US Autism Diagnostic Study
Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians. BlinkLab states in its Wednesday (March 12) release that the study is the largest digital... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00